EBS News and Press, Emergent Biosolutions Inc. From 01/13/20

GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. T...

Full year 2019 preliminary revenues and adjusted profitability metrics in line with prior guidance Full year 2020 forecast reflects continued growth of core business as well as investments in key development programs and operational capabilities GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Wat...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

GAITHERSBURG, Md., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences during the first quarter of 2020: 38 th Annual J.P. Morgan ...

GAITHERSBURG, Md., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon – have been recognized as WomenInc. magazine's 2019 Most Influential Corporate Direct...

Ultra-thinly traded nano cap BioCorRx ( OTCQB:BICX +7.7% ) is up, albeit on only 700 shares, in reaction to encouraging preclinical data on VDM-001, its candidate for the reversal of opioid overdose that it says is an alternative to naloxone. More news on: BioCorRx Inc., Aurobindo Phar...

GAITHERSBURG, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV VLP) vac...

Emergent BioSolutions (NYSE: EBS ) outlines its five-year growth strategy at its Investor Day, aspiring to top $2B in total revenues with 27%-30% adjusted EBITDA margin by the end of 2024. More news on: Emergent BioSolutions Inc., Healthcare stocks news, Read more ...

GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the company’s Analyst and Investor Day held in New York City. Emergent...